AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

AngioDynamics Inc (NASDAQ:ANGO) is set to release its Q4 2025 earnings on Jul 15, 2025. The consensus estimate for Q4 2025 ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

AngioDynamics, Inc. ( NASDAQ: ANGO) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET James C. Clemmer - CEO, President & Director Stephen A. Trowbridge - Executive VP & CFO ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism Multi-center, multi-national study builds on ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment ...